Jexys Pharmaceuticals Ltd.
Sector: Biotechnology - Therapeutics
Medical Field: Immune Disorders
Technological Field: Drug Discovery
Year Established: 2000
Jexys Pharmaceuticals Ltd is an Israeli biopharmaceutical company developing a platform of technologies for screening of new drugs using proprietary Mitogen Activated Protein Kinase MAPKs mutants isolated through molecular evolution. Jexys has already developed and patented active variants of MAPK enzymes that serve as unequivocal targets for drug screening. Using the unique active MAPK enzymes Jexys has developed high throughput screening systems in yeast. In a pilot screen Jexys discovered two novel inhibitors of p38 that are being tested for their anti-inflammatory effect.